Back to drug

The Drug-Induced Respiratory Disease Website

Or 'ILD'. (Fr: PnP subaiguë). A.k.a. pulmonary infiltrates. Generally bilateral and symmetrical. Gradual onset. Consistent with but not specific for an NSIP-c pattern on pathology. Less- dense, severe, acute and diffuse than pattern Ia. Lacks the features of ARDS that may accompany pattern Ia. Can be in the form of disseminated linear, reticulonodular, miliary or patchy opacities. BAL is indicated to separate this pattern from PIE (Ic) or DAH (IIIa). Acute chest pain can be at the forefront. A search for microorganisms including Pneumocystis (stains, PCR) is indicated. On pathology (although not many cases undergo a confirmatory lung biopsy), there is interstitial inflammation and a more or less dense cellular interstitial cellular infiltrate (NSIP-c). Fibrosis, alveolar edema and/or a reactive epithelium denote those cases resulting from with antineoplastic chemotherapy agents. The frontier between patterns Ia and I b can be difficult to draw, so please check drugs under both Ia and Ib. Patients may quickly shift from pattern Ib to Ia particularly if the the causal drug is inappropriately continued. Prompt withdrawal must be considered, underlying disease permitting, and can be therapeutic.

Publications

Shittu I, Oguzie JU, Hernández-Vidal G, Moreno-Degollado G, Silva DB, Marushchak LV, Trujillo-Vargas CM, Lednicky JA, Gray GC

Novel Rodent Coronavirus-like Virus Detected Among Beef Cattle with Respiratory Disease in Mexico.

Viruses 2025 Mar 18;17; — 2025 Mar 18

Schlam I, Giordano A, Tolaney SM

Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer.

Expert opinion on drug safety 2023 Nov 23;; — 2023 Nov 23

Jazieh KA, Budd GT, Dalpiaz N, Abraham J

Can CDK4/6 inhibitors cause fatal lung injury?

Expert review of anticancer therapy 2019 11;19;917-919 — 2019 11 — 917-919